BioTuesdays

Tag - SVac

Prima BioMed to get key CVac data in second half

After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its CVac cancer...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.